These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1384557)

  • 21. Aspects of tuberculosis in Africa. 2. The value of microbiology in the management of tuberculosis in Nairobi, Kenya.
    Brindle R
    Trans R Soc Trop Med Hyg; 1992; 86(5):470-1. PubMed ID: 1475805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cutaneous reactions to thiacetazone (TB1) (author's transl)].
    Strobel M; Ndiaye B; Marchand JP; Jovet JC
    Rev Fr Mal Respir; 1979; 7(5):467-70. PubMed ID: 95055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous manifestations of human immunodeficiency virus in Lusaka, Zambia.
    Hira SK; Wadhawan D; Kamanga J; Kavindele D; Macuacua R; Patil PS; Ansary MA; Macher AM; Perine PL
    J Am Acad Dermatol; 1988 Sep; 19(3):451-7. PubMed ID: 2971691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions.
    Lehloenya RJ; Todd G; Badri M; Dheda K
    Int J Tuberc Lung Dis; 2011 Dec; 15(12):1649-57. PubMed ID: 22118173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of tuberculosis in developing countries.
    Elliott AM; Mwinga AG; Foster SD
    Lancet; 1995 Oct; 346(8982):1098-9. PubMed ID: 7564805
    [No Abstract]   [Full Text] [Related]  

  • 26. Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria.
    Pearson CA
    J Trop Med Hyg; 1978 Dec; 81(12):238-42. PubMed ID: 85717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons.
    Lehloenya RJ; Todd G; Wallace J; Ngwanya MR; Muloiwa R; Dheda K
    Br J Dermatol; 2016 Jul; 175(1):150-6. PubMed ID: 26918554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug reactions. 18. Cutaneous reactions to antituberculous drugs.
    Levantine A; Almeyda J
    Br J Dermatol; 1972 Jun; 86(6):651-5. PubMed ID: 4114691
    [No Abstract]   [Full Text] [Related]  

  • 29. Further consequences of thioacetazone-induced cutaneous reactions.
    Lawn SD; Griffin GE
    Int J Tuberc Lung Dis; 2000 Jan; 4(1):92-3. PubMed ID: 10654652
    [No Abstract]   [Full Text] [Related]  

  • 30. Tuberculosis and human immunodeficiency virus infection in developing countries.
    Harries AD
    Lancet; 1990 Feb; 335(8686):387-90. PubMed ID: 1968123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.
    Elliott AM; Foster SD
    Tuber Lung Dis; 1996 Feb; 77(1):27-9. PubMed ID: 8733410
    [No Abstract]   [Full Text] [Related]  

  • 32. CD4 count and risk of anti-tuberculosis drug-associated cutaneous reactions in HIV-infected Thai patients.
    Boonyagars L; Hirunwiwatkul P; Hurst CP
    Int J Tuberc Lung Dis; 2017 Mar; 21(3):338-344. PubMed ID: 28225346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiforme skin lesions in Yekatit 12 Hospital, 1976-1994.
    Gessesse B; Mulugeta E
    Ethiop Med J; 2000 Jan; 38(1):43-7. PubMed ID: 11144879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tuberculosis in HIV infection.
    Horner PJ; Moss FM
    Int J STD AIDS; 1991; 2(3):162-7. PubMed ID: 1863645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Skin toxicity of thiacetazone (TB1) at a hospital service in Dakar].
    Dieng MT; Ndiaye B; Camara C
    Dakar Med; 2001; 46(1):1-3. PubMed ID: 15773145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
    Kassim S; Sassan-Morokro M; Ackah A; Abouya LY; Digbeu H; Yesso G; Coulibaly IM; Coulibaly D; Whitaker PJ; Doorly R
    AIDS; 1995 Oct; 9(10):1185-91. PubMed ID: 8519456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of Enterocytozoon bieneusi infections among HIV-positive individuals with persistent diarrhoea in Harare, Zimbabwe.
    van Gool T; Luderhoff E; Nathoo KJ; Kiire CF; Dankert J; Mason PR
    Trans R Soc Trop Med Hyg; 1995; 89(5):478-80. PubMed ID: 8560514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical aspects and treatment outcome in HIV-associated pulmonary tuberculosis: an experience from a Thai referral centre.
    Hongthiamthong P; Riantawan P; Subhannachart P; Fuangtong P
    J Med Assoc Thai; 1994 Oct; 77(10):520-5. PubMed ID: 7745373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.